SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:oru-113231"
 

Search: id:"swepub:oai:DiVA.org:oru-113231" > Clinical utility of...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury

Mondello, Stefania (author)
University of Florida, Gainesville, Florida, United States; Banyan Biomarkers, Inc, Alachua, Florida, United States
Linnet, Akinyi (author)
Banyan Biomarkers, Inc, Alachua, Florida, United States
Büki, Andras, 1966- (author)
University of Pecs, Pecs, Hungary
show more...
Robicsek, Steven (author)
University of Florida, Gainesville, Florida, United States
Gabrielli, Andrea (author)
University of Florida, Gainesville, Florida, United States
Tepas, Joseph (author)
University of Florida, Jacksonville, Florida, United States
Papa, Linda (author)
Orlando Regional Medical Center, Emergency Medicine, Orlando, Florida, United States
Brophy, Gretchen M. (author)
Virginia Commonwealth University, Pharmacotherapy & Outcomes Sciences and Neurosurgery, Richmond, Virginia, United States
Tortella, Frank (author)
Walter Reed Army Institute of Research, Silver Spring, Maryland, United States
Hayes, Ronald L. (author)
University of Florida, Gainesville, Florida, USA; Banyan Biomarkers, Inc, Alachua, Florida, United States
Wang, Kevin K. (author)
Banyan Biomarkers, Inc, Alachua, Florida, USA; University of Florida, Gainesville, Florida, United States
show less...
 (creator_code:org_t)
Wolters Kluwer, 2012
2012
English.
In: Neurosurgery. - : Wolters Kluwer. - 0148-396X .- 1524-4040. ; 70:3, s. 666-675
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Brain damage markers released in cerebrospinal fluid (CSF) and blood may provide valuable information about diagnosis and outcome prediction after traumatic brain injury (TBI).Objective: To examine the concentrations of ubiquitin C-terminal hydrolase-L1 (UCH-L1), a novel brain injury biomarker, in CSF and serum of severe TBI patients and their association with clinical characteristics and outcome.Methods: This case-control study enrolled 95 severe TBI subjects (Glasgow Coma Scale [GCS] score, 8). Using sensitive UCH-L1 sandwich ELISA, we studied the temporal profile of CSF and serum UCH-L1 levels over 7 days for severe TBI patients.Results: Comparison of serum and CSF levels of UCH-L1 in TBI patients and control subjects shows a robust and significant elevation of UCH-L1 in the acute phase and over the 7-day study period. Serum and CSF UCH-L1 receiver-operating characteristic curves further confirm strong specificity and selectivity for diagnosing severe TBI vs controls, with area under the curve values in serum and CSF statistically significant at all time points up to 24 hours (P < .001). The first 12-hour levels of both serum and CSF UCH-L1 in patients with GCS score of 3 to 5 were also significantly higher than those with GCS score of 6 to 8. Furthermore, UCH-L1 levels in CSF and serum appear to distinguish severe TBI survivors from nonsurvivors within the study, with nonsurvivors having significantly higher and more persistent levels of serum and CSF UCH-L1. Cumulative serum UCH-L1 levels > 5.22 ng/mL predicted death (odds ratio, 4.8).Conclusion: Serum levels of UCH-L1 appear to have potential clinical utility in diagnosing TBI, including correlating to injury severity and survival outcome.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view